Basic Information
| LncRNA/CircRNA Name | MIR22HG |
| Synonyms | NA |
| Region | GRCh38_17:1711493-1717174 |
| Ensemble | ENSG00000186594 |
| Refseq | NR_028502 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP, etc. |
| Sample | liver cancer tissues, cell line(HEK293T, Huh7, HepG2-C3A, SK-Hep-1 and MHCCLM3 cells) |
| Expression Pattern | down-regulated |
| Function Description | MIR22HG was downregulated in 120 HCC samples compared with adjacent nontumor liver tissues. More interestingly, decreased expression of MIR22HG in HCC could predict poor prognosis of HCC patients. Knockdown of MIR22HG promoted the growth, migration and invasion of HCC cells. In exploring the molecular mechanism of MIR22HG, we found that MIR22HG functioned as a tumor suppressor in hepatocellular carcinomas, in part through serving as a competing endogenous RNA to modulate the miRNA-10a- 5p level. Moreover, NCOR2 was verified to act as the downstream target gene of MIR22HG/miR-10a- 5p. In addition, the MIR22HG/miRNA-10a- 5p/ NCOR2 axis inhibited the activation of the Wnt/?-catenin pathway. Together, our results demonstrated that MIR22HG inhibited HCC progression in part through the miR-10a- 5p/ NCOR2 signaling axis and might act as a new prognostic biomarker for HCC patients. |
| Pubmed ID | 30680848 |
| Year | 2019 |
| Title | LncRNA MIR22HG inhibits growth, migration and invasion through regulating the miR-10a-5p/NCOR2 axis in hepatocellular carcinoma cells |
External Links
| Links for MIR22HG | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |